Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 - AGEN

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. and reminds investors of the November 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against the company [1][3]. Group 1: Legal Action and Investor Information - Investors who suffered losses exceeding $50,000 in Agenus between January 23, 2023, and July 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The complaint alleges that Agenus and its executives violated federal securities laws by making false or misleading statements regarding the effectiveness of their combination therapy, botensilimab and balstilimab [3][4]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. Group 2: Company Performance and Stock Impact - On July 18, 2024, Agenus announced that the FDA advised against the submission of clinical results for accelerated approval, leading to a significant stock price drop of $10.43 per share, or 58.83%, closing at $7.30 per share [4]. - The clinical results and regulatory prospects of botensilimab and balstilimab were reportedly overstated, contributing to the misleading public statements made by the company [3].